To target skeletal muscle MKP-1 to treat metabolic diseases, there is need to design a dual promoter technology in which a skeletal muscle-specific transcription system under the control of a human alpha skeletal actin promoter antisense-based therapeutics against MKP-1. Here, DUSP1 is linked to Other metabolic disease.